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Abstract
Background: Antiretroviral drugs are a very effective therapy against HIV infection. However, the high mutation
rate of HIV permits the emergence of variants that can be resistant to the drug treatment. Predicting drug
resistance to previously unobserved variants is therefore very important for an optimum medical treatment. In this
paper, we propose the use of weighted categorical kernel functions to predict drug resistance from virus sequence
data. These kernel functions are very simple to implement and are able to take into account HIV data particularities,
such as allele mixtures, and to weigh the different importance of each protein residue, as it is known that not all
positions contribute equally to the resistance.
Results: We analyzed 21 drugs of four classes: protease inhibitors (PI), integrase inhibitors (INI), nucleoside
reverse transcriptase inhibitors (NRTI) and non-nucleoside reverse transcriptase inhibitors (NNRTI). We
compared two categorical kernel functions, Overlap and Jaccard, against two well-known noncategorical
kernel functions (Linear and RBF) and Random Forest (RF). Weighted versions of these kernels were also
considered, where the weights were obtained from the RF decrease in node impurity. The Jaccard kernel
was the best method, either in its weighted or unweighted form, for 20 out of the 21 drugs.
Conclusions: Results show that kernels that take into account both the categorical nature of the data and the
presence of mixtures consistently result in the best prediction model. The advantage of including weights depended
on the protein targeted by the drug. In the case of reverse transcriptase, weights based in the relative importance of
each position clearly increased the prediction performance, while the improvement in the protease was much smaller.
This seems to be related to the distribution of weights, as measured by the Gini index. All methods described, together
with documentation and examples, are freely available at https://bitbucket.org/elies_ramon/catkern.
Keywords: HIV, Drug resistance prediction, Categorical kernel, Weighted kernel, PI, NRTI, NNRTI, INI, Machine learning,
Support vector machine, Random Forest, Kernel PCA
Background
HIV is a retrovirus that infects human immune cells,
causing a progressive weakening of the immune system.
When untreated, the affected person develops acquired
immunodeficiency syndrome (AIDS), which leads to a
rise of opportunistic infections and, finally, death. HIV
has infected more than 35 million people worldwide and
is considered a global pandemic [1]. Despite the efforts,
to date there is no definitive cure that eradicates the
virus from the organism. However, the lifespan and quality
of life of many people that live with HIV have expanded
greatly thanks to antiretroviral therapy. Antiretroviral drugs
lower the virus level in blood by targeting different stages
of the virus life cycle. The most important classes of anti-
retroviral drugs are protease inhibitors (PIs), which target
the protease, and nucleoside and non-nucleoside reverse
transcriptase inhibitors (NRTIs and NNRTIs, respectively)
which target the reverse transcriptase. Other classes of anti-
retroviral drugs are the integrase inhibitors (INIs) and the
fusion inhibitors.
Some of the main reasons why HIV is so difficult to
fight are its short life cycle (1–2 days), high replication
rate (108–109 new virions each day), and high mutation
rate (10− 4–10− 5 mutations per nucleotide site per repli-
cation cycle) caused because reverse transcriptase lacks
proofreading activity. This permits the fast emergence of
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new HIV variants, some of which may be resistant to the
drug treatment [2]. These variants can be transmitted,
and some studies show that ~ 10% of patients who had
never been on antiretroviral therapy carry at least one
resistant HIV [3]. Cross-resistance (simultaneous resist-
ance to two or more drugs, often of the same class) is
also a common phenomenon. It is therefore advisable to
do a resistance test before the treatment to find the best
drug choice [2, 4], especially in developing countries, as
recommended by the WHO and the International AIDS
Society-USA Panel [3]. A resistance test can be per-
formed in vitro, obtaining HIV samples from the patient
and using them to infect host cells cultured in presence
of increasing levels of drug concentration. The virus sus-
ceptibility is then obtained empirically as the IC50 [4]
and usually delivered as the relative IC50 (resistance of
the virus variant compared to the wild type). Another
strategy is to infer the HIV variant resistance from its se-
quence. This can be either gene sequence or the trans-
lated protein sequence; this latter approach eliminates
the noise of synonymous mutations. In any case, as gen-
ome sequencing is cheaper, faster and more widely available
than performing an in vitro drug susceptibility test, much
effort has been invested in developing algorithms that pre-
dict the drug resistance from the virus sequence [5].
The first attempts of automatic prediction can be
traced back, at least, to the early 2000s [6]. These
approaches were rule-based: study the mutational
profile of the HIV variant to look for known major
drug-associated resistance mutations (lists of these
mutations are periodically updated and can be found
in reviews, e.g., [7]). The rule-based algorithms con-
tinue to be used to this day because of their inter-
pretability. Some publicly available examples are the
Stanford HIVdb, Rega or ANRS softwares [5]. How-
ever, the aforementioned high mutation rate of the
HIV, which favors the emergence of large numbers
of new resistance mutations and complex mutational
patterns, makes the rule-based approach suboptimal.
In this scenario machine learning methods can be
extremely helpful, especially in recent years with the
increasing size of available data. This second ap-
proach is also very popular and there exists machine
learning software to predict resistance online [8, 9].
Different methods have been proposed, the most
common ones being Linear Regression [10, 11], Arti-
ficial Neural Networks (ANN) [10, 12–14], Support
Vector Machines (SVMs) [10, 15, 16], Decision Trees
(DT) [10, 17] and their ensemble counterpart, Ran-
dom Forests (RF) [15, 16, 18, 19]. Some machine
learning studies have complemented the sequence data
with structural information, e.g., [11, 15, 16, 18], or have
benefited from the knowledge about major drug associ-
ated mutations to perform feature selection. The inclusion
of cross-resistance information in the form of ensemble
methods has also been reported to improve resistance pre-
diction [20–22].
Nevertheless, HIV sequence data specificities pose sig-
nificant challenges to resistance prediction. First, se-
quence data is categorical in nature. However, most
machine learning algorithms are designed to cope with
numeric data (DT and RF being exceptions), thus obli-
ging to perform some kind of pre-processing. A typical
approach is to recode each position into m or m − 1
“dummy variables”, which can take the values 0 or 1 [5].
Usually, m is the number of all possible alleles that can
be potentially found in a position (i.e., m = 20 in protein
sequences). However, some authors restrict the dummy
variables to the drug associated mutations already
appearing in the literature [6, 10, 12]. A very different
approach is found in [14], where each amino acid was
codified as an integer ranging 1–22 (the 20 canonical
amino acids plus two extra characters B and Z). Other
encodings have been used with HIV sequence data, like
amino acid composition frequencies, reduced amino acid
alphabets or physicochemical properties [5, 16, 20].
Another challenge is the presence of mixtures of al-
leles (normally two, rarely three or four) in at least one
position of the viral sequence for most clinical samples.
In the case of HIV, this event indicates that the patient
carries two or more virus variants [4]. It is well estab-
lished that HIV tends to generate viral swarms of closely
related viruses (quasispecies), as a consequence of its
high mutation rate [2]. Mixtures introduce ambiguity in
the genotype-phenotype correlation [6] and a problem
of technical nature: the vast majority of machine learn-
ing methods are not able to deal directly with these
“multiallelic” codes. To our knowledge, algorithms so far
have handled allele mixtures with some sort of previous
pre-processing of the data, e.g., keeping only the most
frequent amino acid of the mixture [19], replacing the
positions by a missing value [17], excluding the affected
sequences [15] or expanding the data to obtain all the
possible sequences that could be generated with the ob-
served mixtures [11, 14, 18].
In this paper, we propose the use of kernel functions
specifically adapted to the aforementioned HIV data in-
tricacies, and able to integrate the relevance of the major
resistance associated protein residues. Kernels are math-
ematical functions with interesting properties. They can
be coupled to numerous machine learning algorithms,
the so-called kernel methods, and provide a framework
to deal with data of virtually any type (e.g. vectors,
strings, graphs). They can also encode complementary
knowledge about a problem, as long as some mathemat-
ical conditions are satisfied [23]. Our aim using kernel
functions that address the aforementioned HIV data par-
ticularities was not only to improve prediction, but also
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reduce pre-processing, thus preserving the data integrity
and lowering the risk of inserting spurious patterns.
Methods
Datasets and data pre-processing
The Genotype-Phenotype Stanford HIV Drug Resistance
Database [24] is a public dataset with sequences from
HIV isolates and its relative susceptibility to several anti-
retroviral drugs. We retrieved the PhenoSense dataset
from Stanford webpage (version date: 2019-2-20). The
data is split in four databases (PI, NRTI, NNRTI and
INI), which contain between 1,000–3,500 HIV isolates.
INI is a new addition to the Stanford database and in-
cludes some of the drugs most recently approved for
therapeutic use. The complete dataset contains eight
protease inhibitors: atazanavir (ATV), darunavir (DRV),
fosamprenavir (FPV), indinavir (IDV), lopinavir (LPV),
nelfinavir (NFV), saquinavir (SQV) and tipranavir (TPV);
five integrase inhibitors: bictegravir (BIC), cabotegravir
(CAB), dolutegravir (DTG), elvitegravir (EVG) and ralte-
gravir (RAL); and two classes of reverse transcriptase in-
hibitors: six NRTIs, lamivudine (3TC), abacavir (ABC),
zidovudine (AZT), stavudine (D4T), didanosine (DDI) and
tenofovir (TDF); and four NNRTIs, efavirenz (EFV), etra-
virine (ETR), nevirapine (NVP) and rilpivirine (RPV). Se-
quence length is 99 amino acids in the case of PI database,
288 in the case of INI database and 240 in the case of
NRTI and NNRTI databases. The dataset contains the
strain virus resistance (relative IC50) to each drug, and the
sequence of the protein targeted by this drug. We built
the regression models for each drug separately, taking
each polymorphic protein position as a predictor variable
and the drug resistance value as the target variable. Since
the distributions of resistances are highly skewed we used
the log-transformed values, as recommended in [5]. Re-
dundant viruses obtained from the same patient were re-
moved to minimize bias. We deleted all sequences
affected by events that changed protein length (protein
truncations, insertions and deletions). These events were
uncommon in the dataset and affected less than 5% of
HIV sequences. Also, we removed all isolates with one or
more missing values. Missing values are present in the tar-
get variables as well as in the sequences, because not all
HIV isolates have been tested for all drugs. The final num-
ber of data instances for each drug is shown in Table 1.
To ensure a minimum of data rows for training/test parti-
tions and cross-validation, we did not consider drugs with
a sample size lower than 100.
Methods
We compared the performance of a nonlinear, nonkernel
method (RF) to a kernel method: SVMs. SVMs can be
either linear or nonlinear, depending on the kernel used.
The linear kernel is the simplest of all kernel functions,
given by the inner product of two vectors in input space,
x and y:
kLin x; yð Þ ¼ xTy ð1Þ
In our case, x and y represent the protein sequence of
two HIV isolates, recoded as dummy variables [25]. We
used this kernel as the linear method of reference. An al-
ternative expression is:
kLin x; yð Þ ¼
Xd
i¼1
wixiyi ð2Þ
where d is the length of the sequence. This expression
stresses the possibility of assigning a weight wi to each
protein position, as it is known that not all positions
contribute equally to the virus resistance [2]. Weights
are nonnegative and sum to one. We considered two op-
tions: the simplest one was to consider that all positions
have the same importance, i.e., assigning equal weight 1/
d to all variables. The second one was including additional
information into the kernels, using RF mean decrease in
node impurity as a metric for position importance.
RBF kernel
It is a nonlinear kernel, usually defined as:
kRBF x; yð Þ ¼ e−γ x−yj jj j
2 ð3Þ
Where ||x − y||2 is the squared Euclidean distance be-
tween two vectors, and γ > 0 is a hyperparameter. As in
the case of the linear kernel, the original data was
recoded. We also introduced the possibility of weighting
the positions:
kRBF x; yð Þ ¼ e−γ
Pd
i¼1 wi xi−yið Þ
2 ð4Þ
The RBF kernel is a widely accepted default method
[23, 25], so we used it as a benchmark to compare with
the categorical kernels.
Overlap kernel
This is the most basic categorical kernel. This kernel as-
signs 1 if the two instances compared are equal and 0
otherwise.
Table 1 Final number of HIV isolates per drug
Drug Data
size
Drug Data
size
Drug Data size Drug Data
size
ATV 1058 SQV 1603 DDI 1511 BIC 84
DRV 665 TPV 766 TDF 1236 CAB 0
FPV 1559 3TC 1482 EFV 1511 DTG 209
IDV 1607 ABC 1513 ETR 502 EVG 577
LPV 1372 AZT 1502 NVP 1517 RAL 636
NFV 1654 D4T 1510 RPV 181
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kOv xi; yið Þ ¼
1 if xi ¼ yi
0 if xi≠yi

ð5Þ
where xi and yi represent the alleles of a given protein
position i in two HIV sequences, x and y.
Jaccard kernel
The Jaccard index measures the similarity between two
finite sets and is a valid kernel function [26]. We used it
to handle allele mixtures, while in the rest of methods
we randomly sampled one allele of the mixture. Letting
again i denote a given protein position (so that Xi and Yi
are non-empty sets of alleles in the i-th position for iso-
lates x and y) then:
kJac Xi;Y ið Þ ¼ j Xi∩Y i jj Xi∪Y i j ð6Þ
When ∣Xi ∣ = ∣ Yi ∣ = 1, i.e., none of the individuals
have an allele mixture at that i-th position, Jaccard re-
duces to the Overlap kernel. Unlike Overlap, the Jaccard
kernel can deal simultaneously with allele mixtures and
categorical data.
“RBF-like” categorical kernels
For the whole protein sequences, we can aggregate all
single position Overlap and Jaccard evaluations as the
convex combination of kernels evaluations (Eq. 5 or 6)
and position weights. This results in a valid kernel func-
tion, since the product of a positive scalar and a kernel
is a kernel, and the sum of kernels is also a kernel. To
ensure that the only difference between categorical ker-
nels and RBF was the categorical part, we introduced an
exponential factor and the hyperparameter γ, in a way
analogous to (3) and (4):
kcat x; yð Þ ¼ e−γeγ
Pd
i¼1 wik xi;yið Þ ð7Þ
This is also a valid kernel function, since the exponen-
tial of a kernel gives another kernel, and where e−γ nor-
malizes the kernel matrix, keeping the evaluations
between 0 and 1. The final versions of the Overlap and
the Jaccard kernels are obtained replacing the k(xi, yi)
term by (5) or (6), respectively. In our analyses, we com-
pared weighted and unweighted versions for all linear,
RBF, Overlap and Jaccard kernels. Thus we can ensure a
fair comparison between the categorical and the nonca-
tegorical kernels.
Stacked models
So far, we have built prediction models for each inhibitor
separately. As mentioned in the Introduction, it is reported
that there exists some degree of relationship between the re-
sistance of different drugs (e.g. in case of cross-resistance).
To check whether the use of this information can improve
prediction, we implemented the stacking algorithm de-
scribed in [22] for continuous outcomes. This meta-learner
approach consists of two principal steps. In the first step,
single drug models are built from the training data as usual.
In the second step, the fitted values (i.e. predictions of the
training data) of all drugs obtained in step 1 are used as in-
put to a new (stacked) model, being each drug a different
predictor. The method that integrates the single drug
models in step 2 and delivers the definitive predictions is
called a combiner algorithm. Data size largely varied be-
tween drugs (see Table 1), even within the same drug class,
so we chose Decision Trees (DT) as our combiner algo-
rithm, as they can easily handle missing data. We combined
the drugs within the same database (PI, NRTI, NNRTI and
INI) and applied this stacking methodology to our previ-
ously proposed weighted kernels (Linear, RBF, Overlap and
Jaccard).
Experimental setup and model tuning
To assess the performance of the methods used, each data-
base was split at random in two partitions: training set
(60% of the database) and test set (40%). Hyperparameter
optimization was done by a 10 × 10 cross-validation on the
training set. Once the optimum hyperparameter was found,
the final model was built using the whole training set. To
assess the model performance, the NMSE (Normalized
Mean Square Error) between the actual and the predicted
drug resistances of the test set was computed:
NMSE observed; predictedð Þ
¼
P
observed−predictedð Þ2
N−1ð Þ  var observedð Þ ð8Þ
NMSE can be understood as the fraction of target
variance not explained by the model.
We repeated the whole process 40 times, each time
with different 60/40 randomly split training/test parti-
tions, to obtain an error distribution. Kernel position
weights were calculated using the training set only.
Note that only the Jaccard kernel can directly handle
allele mixtures; for the rest of kernels and the RF, we
generated 40 versions of the database randomly sam-
pling one allele at a time. Then, the 40 replicates
were used to compute all the models except Jaccard,
which could deal directly with the database without
further preprocessing. This way we can ensure an
honest comparison between Jaccard and the rest of
kernels and methods.
All analyses were implemented in the R statistical
computing language [27]. A documented package imple-
menting these methods is available at https://bitbucket.org/
elies_ramon/catkern/.
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Visualization
Kernel PCA is a kernel method obtained by coupling ker-
nel functions to a Principal Components Analysis. We
used the Jaccard kernel PCA to visually check whether se-
quences that are considered more similar by the kernel
function are also similar in their drug resistance. As this
method is for visualization purposes only, we did not sep-
arate training and test sequences. Thus, we used the mean
kernel weights of the 40 training sets to compute the
weighted Jaccard.
To check whether the important protein positions (i.e.
kernel weights) detected by RF could have an structural
relevance, we highlighted our top ranking positions on
the tridimensional structure of the protein. Pictures of
protein-drug complexes were generated with Molsoft
ICM-Browser v.3.7–2 using structural data obtained
from RCSB Protein Data Bank.
Performance comparison to other approaches
We compared our SVM plus weighted Jaccard with the
ANN approach described in [14], which to our knowledge
achieves the best performance so far in this dataset. We
used the R interface to keras to implement the ANN. First,
we followed the specifications described in [14] about the
range of candidate architectures (1–3 hidden layers, with
2–10 nodes per layer, for all drugs), number of epochs and
early stopping. As our dataset version and data pre-process-
ing differ from [14], we also evaluated a different range of
hyperparameters: three fixed ANN architectures (one hid-
den layer with 30 nodes, two hidden layers with 20 and 10
nodes respectively, and three hidden layers with 30, 20 and
10 nodes) with the L2 regularization parameter λ. Both ap-
proaches (from now on referred to as ANN1 and ANN2)
were trained and tested as for the rest of methods (see:
Data and dataset pre-processing), with the previously de-
scribed 40 replicates, allele mixture treatment, training/test
ratio and 10 × 10 cross-validation to choose the best num-
ber of layers and nodes per layer (in the case of ANN1) or
λ (in the case of ANN2). We chose the best architecture
obtained in training within ANN1 and ANN2 options for
each drug.
Results
As expected, HIV protein sequences showed a large vari-
ability. As many as 93% of the protease positions were
polymorphic and, among these, the number of different
observed alleles varied between 2 and 16. In the case of
reverse transcriptase, 89% of the positions were poly-
morphic and the number of alleles per polymorphic pos-
ition ranged between 2 and 14. Integrase was the least
variable protein: 75% of the positions were polymorphic
and, in these positions, the number of alleles ranged be-
tween 2 and 8. Almost 60% of the sequences had at least
one allele mixture.
Figure 1 shows the NMSE distribution boxplot for four
representative drugs: FPV (PI database, panel a), DDI
(NRTI database, panel b), NVP (NNRTI database, panel c)
and EVG (INI database, panel d). The remaining 17 box-
plots can be found at Additional file 1: Figures S1-S17.
Performance overview
NMSE varied greatly across drugs and methods. The
best prediction was achieved for 3TC, with an average
NMSE ranging 0.07–0.16 depending on the method used
(Additional file 1: Figure S8). The drug with worst pre-
diction error was DTG, with an average NMSE ranging
0.65–0.75 (Additional file 1: Figure S16). This was also
the second drug with lowest data size (Table 1). Not un-
expectedly, methods applied to drugs with low N had
considerably worse performance overall (especially DTG,
RPV, ETR and TPV, but also TDF and to some extent
DRV). In the PI database, errors were fairly similar
across all drugs and around 0.12–0.20 on average (e.g.
Figure 1a), with the sole exception of TPV, with an aver-
age NMSE ranging 0.30–0.45. In turn, predictive perfor-
mances for the integrase and reverse transcriptase
inhibitors were far more variable across drugs. Overall,
the best method was the SVM with the Jaccard kernel
(either in its weighted or in its unweighted version),
which achieved the best performance in 20 out of 21
drugs.
Unweighted case
Nonlinear kernels performed much better than the lin-
ear kernel in almost all drugs, with the only exception of
ETR and D4T. Categorical kernels outperformed RBF,
although RBF was close to Overlap (or even marginally
better) in some cases. Among categorical kernels, the
Jaccard kernel performed better than Overlap in all in-
hibitors, sometimes by a large margin, as in the cases of
SQV, 3TC, AZT, EFV, NVP, RAL or EVG (Fig. 1 c and
d). Predictive performances of unweighted kernels and
of RF were markedly different in protease with respect
to integrase and transcriptase inhibitors. RF was consist-
ently worse than kernel methods for the PI database (e.g.
Figure 1a), whereas RF performance was comparable or
better than those of kernel methods in both reverse tran-
scriptase and integrase inhibitors (e.g. Figure 1b, c and d).
Weighted case
Figure 2 shows three representative examples of the
weights obtained from RF. The remaining plots are
shown in Additional file 2: Figures S18-S35. We ascer-
tained that RF detected most of the major resistance
associated positions described in the literature (e.g. re-
view in [2]). Overall, a higher percentage of relevant po-
sitions were identified in protease inhibitors than in
both reverse transcriptase and integrase inhibitors. To
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evaluate this numerically, we computed the Gini index of
the RF importance distributions for each of the drugs. This
index is shown in Fig. 2 and Additional file 2. We also no-
ticed differences regarding the location of the important
positions in the tridimensional structures of protease
(Fig. 3a) and reverse transcriptase (Fig. 3b). The most im-
portant protease positions according to RF are distributed
over the whole structure, whereas in the case of the reverse
transcriptase they are located at the drug binding site.
As for predictive performance, weighting was more ef-
fective in integrase and reverse transcriptase inhibitors
than in protease inhibitors. In NRTI and NNRTI data-
bases, weighted kernels outperformed RF in all cases,
whereas their unweighted counterparts did not. This
was particularly the case for 3TC, DDI (Fig. 1b), EVG
(Fig. 1d) and especially NVP (Fig. 1c), where weighting
decreased the Jaccard kernel error by around 50%. In
contrast, the effect of weighting was less marked in the
PI database: similar errors were obtained (e.g. Figure 1a)
for all drugs but TPV, where the error actually increased.
In the INI database, weighting decreased dramatically
the error in RAL and EVG drugs but not in DTG. In
summary, Jaccard was the best weighted kernel followed
by Overlap, RBF and Linear.
Factors affecting prediction error
To investigate the relevance of each factor in prediction,
we fitted the following linear model to NMSE obtained
in each replicate across all kernels and drugs (40 repli-
cates × 21 drugs × 8 kernels):
NMSE  N þ K þW þ GINI þ ε ð9Þ
where N is the drug data size (Table 1), K is a class vari-
able with the kernel used (Linear, RBF, Overlap or
Jaccard), W= 0 or 1 depending on whether the kernel
was unweighted or weighted, respectively, and GINI is
the standardized Gini index of RF weights. Table 2 sum-
marizes the coefficients and their significance. We found
that all factors are significant and behave additively (in-
teractions were not significant; results not shown). As
expected NMSE decreases with N but, interestingly, also
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with Gini index, i.e., prediction improves when there are
only a few positions of large effect. Categorical kernels
were consistently better than noncategorical ones and
Jaccard was the best option in all cases. Weighting pro-
tein positions significantly lowers the error, although only
in reverse transcriptase and integrase inhibitors (as also
observed in Fig. 1 and Additional file 1: Figures S1-S17).
To visualize the impact of Gini index not ascribable to
the effects of data size (N) and the kernel used (K), we
plotted the residuals of model NMSE ~ N+K + ε against
GINI (Fig. 4 panels a, b and c). For protease inhibitors, the
Gini effect is confined to TPV drug (red dots in Fig. 4a).
The effect is rather linear for reverse transcriptase inhibi-
tors, although NMSE variability was larger than average
for RPV (red dots), the drug with lowest N. In the case of
integrase inhibitors, Gini takes values in a narrow range
and does not seem to have an impact on prediction. As in
the case of RPV, large variability in NMSE values is ob-
served in DTG (blue dots), which is the drug with second
lowest sample size.
Sample size is one of the most important factors in
any experimental design, and the main one influencing
total cost. Figure 4 panels d, e and f show the residuals
of model NMSE ~ K +W+GINI vs. N. Although Table 2
shows that the NMSE decreases with sample size for all
drugs and proteins, a clear trend appears only for re-
verse transcriptase inhibitors. In this case, a law of
diminishing returns is observed, and adjusted NMSE de-
crease with N is very small for N > ~ 600.
Kernel PCA
Even if weighting increases prediction accuracy overall,
the effect was markedly different when we compare re-
verse transcriptase and integrase with protease (Table 2).
In the latter protein, weighted kernels were not clearly
superior. To further investigate this issue, we performed
a PCA on the Jaccard kernel. Figure 5 shows the results
of for FPV (a protease inhibitor, panels a and b) and
NVP (a reverse transcriptase inhibitor, panel c and d),
both with unweighted and weighted Jaccard kernels. The
*
*
* *
**
*
***
*
*
Mean Gini index = 0.85
0.0
0.1
0.2
0.3
0.4
0 10 20 30 40 50 60 70 80 90 100
R
F
 w
ei
gh
ts
FPVa
**
*
** *
*
*
*
**
Mean Gini index = 0.93
0.0
0.1
0.2
0.3
0.4
0 10 20 30 40 50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 200 210 220 230 240
R
F
 w
ei
gh
ts
NVPb
*
*
* ***
*
*
Mean Gini index = 0.93
0.0
0.1
0.2
0.3
0.4
0 10 20 30 40 50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 200 210 220 230 240 250 260 270 280 290
Protein position
R
F
 w
ei
gh
ts
EVGc
Fig. 2 RF relative importance of each protein position for three drugs: a protease inhibitor (a), a reverse transcriptase inhibitor (b) and an
integrase inhibitor (c). Standard error across the 40 replicates is marked with error bars. Asterisks highlight the major drug related positions
reported in the literature [2]
Ramon et al. BMC Bioinformatics          (2019) 20:410 Page 7 of 13
remaining figures can be found at (Additional file 4: Fig-
ures S36-S54). Unweighted kernel PCA results, overall,
in a good, spectrum-like separation between resistant
and susceptible isolates for protease inhibitors, whereas
weighted kernels can improve dramatically the separ-
ation in the case of reverse transcriptase. The integrase
inhibitors RAL and EVG behave similarly to reverse
transcriptase inhibitors, while DTG (which has a very
small sample size) do not achieve a good separation ei-
ther in the weighted or the unweighted kernel PCAs.
Stacked models
We compared the performances of four methods (SVM
plus weighted Linear, RBF, Overlap and Jaccard kernels)
with those of their stacked counterparts in Additional file 3:
Tables S1 (mean NMSE) and S2 (NMSE standard error).
Intriguingly, we found that the stacked versions of SVM
with weighted kernels have similar performances to those
of the individual models. This suggests that all the infor-
mation of the sequence has been already extracted in the
first step, and so stacking the models was of no additional
value.
Performance comparison to other approaches
Figure 6 shows the performance comparison between
our best method (SVM with weighted Jaccard kernel)
with the ANN1 and ANN2 (see “Performance compari-
son to other approaches” in Material and methods).
ANN2 tends to have better performance than ANN1,
especially in drugs with small sample size, but also pre-
sents greater standard errors in some drugs. In the case
of protease inhibitors (panel a) both ANN1 and ANN2
Fig. 3 a Wild type protease (in yellow and blue) with an inhibitor (NFV, in green) (PDB code: 3EKX). We highlight the ten most important
positions according to RF: 10, 90, 54, 46, 71, 88, 84, 30, 20 and 82. These positions are scattered throughout the protein and only a few belong to
the drug binding site (e.g. 30, 82 and 84). Mutations at the binding site reduce the affinity for the inhibitor, but can impair the protease catalytic
activity as a collateral damage. Mutations in distant residues are typically concurrent with these binding site mutations and often have a
compensatory role (e.g. stabilizing the protease structure or restoring the catalytic activity). Position 30 appears to be important only in the case
of the NFV drug, while the other positions are found in all (or almost all) protease inhibitors. This agrees with the literature [2]. b Binding pocket
of the reverse transcriptase (in yellow) with an NNRTI (NVP, in pink) (PDB code: 3V81). We highlight the five most important positions for NVP
according to RF: 103, 181, 190, 188 and 101. All these positions reside in the NNRTI binding pocket of the enzyme, and also appear in the other
NNRTIs analyzed. Thus, in EFV, we find 100 (but not 181) in the top 5; and in ETR, we have 179 instead of 188 (also highlighted). Positions 103
and 101 are located near the entry of the inhibitor binding pocket and, when mutated, interfere with the entrance of the inhibitor to the binding
site. Y181 and Y188 have a crucial contribution the NVP binding via stacking interactions between its side chains and the inhibitor aromatic
groups. G190 mutations lead to resistance through steric hindrance, because of the substitution by a more voluminous side chain. L100 effect is
also related to steric hindrance [2]
Table 2 Linear model coefficient estimates and p-values
All drugs PIs NRTIs + NNRTIs INIs
N increment −2.1·10− 4 *** −2.0·10− 5 *** −1.8·10− 4 *** −1.3·10− 3 ***
Unweighted → Weighted −2.0·10− 2 *** 2.0·10− 3 −3.4·10− 2 *** −3.1·10− 2 ***
Gini Index increment −4.9·10− 3 *** −6.0·10− 2 *** −5.4·10− 2 *** 1.7·10−2 **
Jaccard→ Linear 4.5·10−2 *** 2.1·10−2 *** 5.0·10− 2 *** 9.4·10− 2 ***
Jaccard→ RBF 2.5·10− 2 *** 1.3·10− 2 *** 2.8·10− 2 *** 4.7·10− 2 ***
Jaccard→ Overlap 1.9·10− 2 *** 9.3·10− 3 *** 2.1·10− 2 *** 3.6·10− 2 ***
Legend: Significance codes are 0 *** 0.001 ** 0.01 * 0.05
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are only marginally worse than the weighted Jaccard
SVM, with the exception of the FPV drug. In the case of
reverse transcriptase and the integrase inhibitors (panels
b, c and d), the difference between the performance of
weighted Jaccard and the ANN increases. The latter
method presents higher NMSE and larger standard er-
rors, especially for 3TC, DDI, TDF, the NNRTIs, and the
INIs.
Discussion
Recent results on predicting HIV drug resistance as a re-
gression problem can be found in [14, 18]. Shen et al.
[18] used RF and computed the 5-fold cross-validation
R2. Sheik Amamuddy et al. [14] used ANN and com-
puted the R2 of the test set without replicates. The two
approaches were based in a previous version of the
Stanford dataset (version date: 2014-9-28) and share a
similar treatment of amino acid mixtures based on se-
quence expansions. We did a comparison with the ANN,
which to our knowledge achieved the best performance so
far in this dataset [14]. We observed that weighted Jaccard
outperforms ANN in all drugs, and that the ANN predic-
tion performances were worse than those originally re-
ported (which had R2 values ranging between of 0.85 and
0.99). It has to be stressed, however, that we used different
versions of the dataset (the version used by [14], for in-
stance, did not contain information about the INIs) and
that we followed very different strategies concerning pre-
processing. In [14] a pre-processing with removal of out-
liers and rare variant filtering is performed, which can result
in a loss of generalizability, as is acknowledged by the au-
thors. Another reason for the discrepancy is probably the
treatment of allele mixtures, as we discuss next.
In this work, we present a novel approach to predict
drug resistance in HIV, using kernel functions that directly
address the presence of allele mixtures and the categorical
nature of the data. Previous work handled these two issues
using several pre-processing strategies. Categorical data
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are systematically recoded into numeric data, usually in
the form of dummy data or, in [14], assigning an integer
to each category. Here, we have shown that addressing the
categorical nature of the data and the presence of allele
mixtures does lower the test error in comparison to the
dummy variable approach (Table 2). In fact, even the sim-
plest categorical kernel (i.e. the Overlap kernel) improves
prediction upon the standard RBF kernel, although the ex-
tent of the improvement depends on the specific drug. It
has to be stressed that recoding the categorical data into
dummy variables increases the dimensionality of the prob-
lem, thus increasing computation needs and leading to
sparse datasets. As this effect depends on the number of
different categories of the variables, categorical methods
may be more useful when data has more than few categor-
ies. Coding the different alleles as an integer does not in-
crease the dimensionality either, but introduces an order
without biological meaning among the amino acids.
The treatment of amino acid mixtures is more chal-
lenging. In the data analyzed we observed that it is a
widespread phenomenon: about 60% of the sequences
had at least one mixture. Mixtures introduce ambigu-
ity in the genotype-phenotype correlation since it
makes impossible to know the actual sequences of
strains. Also, the quasispecies distribution may have
undergone undefined modifications during the in vitro
assay [28]. Previous approaches to deal with this issue in-
cluded keeping the most frequent amino acid of the mix-
ture [19] and sequence expansion [11, 14, 18]. The latter
strategy consists on expanding the data to sequences with
single amino acids at each mixture location until all pos-
sible combinations have been exhausted. These “derived”
sequences share the resistance value, i.e., the resistance of
the original sequence. This approach dramatically enlarges
data size (in the aforementioned works, minimum by a
10x factor in the protease inhibitors and almost a 30x in
the reverse transcriptase inhibitors). This might be one of
the main reasons for the discrepancy between the ANN
performance computed in this work and in [14]. Without
expansion, the data size ranges between 200 and 1500, but
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the number of (dummy) variables is almost 2000 in the
PIs, and more than 4000 in the other drugs. The higher
number of variables compared to observations might have
adversely affected the ANN performance in comparison
to the original work and, also, in comparison to SVMs, as
the latter are less prone to over-fitting. Furthermore, the
expansion potentially biases the dataset by over represent-
ing sequences with mixtures (especially those with a larger
number of mixtures and/or alleles per mixture) and it can
generate HIV variants not found in the patient. Expansion
also increases the difficulty of the training/test splitting
because all expansions of the same sequence must be
placed either in the training set or in the test set; other-
wise, the independence of both sets is lost. In our work,
we preferred keeping only one amino acid of the mixture,
which is allegedly the most conservative pre-processing
choice. This differs from e.g. [19], because we keep one
amino acid at random, while they pick the most frequent
one, which is sound if mixtures are considered a technical
artifact. However, in case of HIV, this event mostly reflects
the coexistence of actual HIV variants in the body of the
patient [2, 4, 6, 28] and the ambiguity lies in the resistance
value delivered via the in vitro test. In any case, part of the
original information is lost by picking one of the allele of
the mixture. This does not happen when using the Jaccard
kernel, which naturally handles allele mixtures. We have
shown that Jaccard is clearly the best among kernels
assessed and that also improves the RF results, in most
cases by a large margin. Both Overlap and Jaccard are
basic kernel functions, but our kernel definition (7) is
general enough to replace them for more sophisticated
categorical kernels, perhaps with improved prediction
performance.
An additional theoretical proposal was to weigh kernel
positions according to its inferred influence on drug re-
sistance. Here we employed RF decrease in impurity as
weights but numerous options are equally justified and
so additional research on this topic is warranted. Using
RF we were able to identify, from protein sequence
alone, important positions for the drug resistance that
have a structural meaning (Fig. 3). We observed a dis-
tinct effect of weighting in protease inhibitors and tran-
scriptase reverse inhibitors that correlates with the
distribution of the importances. At least part of this
behavior might be due to differences in the mutational
pattern between the two enzymes in regards to drug re-
sistance. In the reverse transcriptase, the major resist-
ance mutations tend to be located in specific positions,
particularly at the drug binding sites of the N-terminal
side, weakening the affinity between drug and enzyme.
As early as 1998, it was noted that a single mutation of
the reverse transcriptase may confer high resistance to
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drugs like 3TC and NVP [28], whereas the virus acquires
resistance to protease inhibitors by accumulating muta-
tions. First, primary resistance mutations arise at the ac-
tive site pocket and the surrounding residues. But, as
these mutations often cause conformational changes,
additional secondary mutations that compensate the im-
paired catalytic activity and stabilize the protease tend to
be selected in turn [2]. There are at least 36 important
residues (out of a total of 99) involved in protease drug
resistance mutations and (unlike reverse transcriptase)
they are distributed along the whole sequence [2]. These
differences may explain why RF, and therefore the
weighted categorical kernels, performed better at the
NRTI and NNRTI databases. Further, the estimate of the
variable importance is more reliable when few relevant
protein positions have a large impact on resistance. In
contrast, the compensatory secondary mutations of the
protease probably introduce some degree of correlation
between protein positions, which may explain why
weighting in PI database does not result in a clear im-
provement of performance.
Conclusions
Machine learning is an effective approach to predict
HIV drug resistance, and a straightforward alternative to
the much slower and expensive in vitro assay. Results
show that kernels that take into account both the cat-
egorical nature of the data and the presence of mixtures
consistently result in the best prediction model. As for
the introduction of position weights, we found that the
amount of improvement was a function of the number
of positions with large effect on drug resistance, which
may be related to the known different mutational pat-
terns regarding drug resistance among the viral proteins.
Using more sophisticated categorical kernels and/or ker-
nels able to take into account structural information
may improve even more the resistance prediction.
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